Press release
Glioblastoma Multiforme Treatment Market to Surge 10.1% Growth Expected 2022-2032
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7187
Market Opportunity:
The Glioblastoma Multiforme Treatment Market offers significant opportunities for growth and innovation. These opportunities include the exploration of novel therapeutic approaches, such as immunotherapies, targeted therapies, and precision medicine, to meet the demand for more effective and less toxic treatments. Additionally, the expanding target population, driven by the increasing incidence of GBM and an aging demographic, provides a chance for heightened market penetration. Furthermore, investment in research and development for innovative therapies, biomarkers, and diagnostics can pave the way for personalized GBM treatment, offering companies a competitive advantage.
Market Challenges:
GBM poses a significant challenge due to its notorious treatment resistance, necessitating extensive research and innovative approaches for the development of effective therapies. The high development costs in the oncology sector, characterized by substantial financial investments in clinical trials and regulatory approvals, present a hurdle for companies. Stringent regulatory requirements and complex approval processes further impede the timely introduction of innovative therapies, requiring companies in the GBM market to navigate these obstacles to bring new treatments to patients.
Key Players:
Merck & Co., Inc.
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Amgen, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Arbor Pharmaceuticals, LLC
Amneal Pharmaceuticals
Karyopharm Therapeutics, Inc.
Sumitomo Dainippon Pharma Oncology, Inc.
Competitive Landscape:
Leading companies in the glioblastoma multiforme treatment market are strategically prioritizing research and development (R&D) initiatives to secure a competitive advantage. They are also actively engaging in mergers, acquisitions, licensing agreements, and collaborations to broaden their product portfolios, bolster manufacturing capabilities, and establish a distinctive competitive position.
Recent advancements in glioblastoma multiforme treatment include:
In April 2021, Lineage Cell Therapeutics entered a licensing agreement with Immunomic Therapeutics to develop allogeneic VAC, a cancer immunotherapy platform, specifically targeting glioblastoma multiforme. The agreement involves an upfront payment of US$2 million for Lineage, with an additional US$67 million in commercial milestone payments.
In July 2020, Denovo Biopharma, a San Diego-based biotech company, gained approval from the U.S. Food & Drug Administration (FDA) for its phase 2b clinical trial. This trial aims to assess an analytical combination therapy for newly diagnosed glioblastoma multiforme patients.
In May 2019, Merck announced its acquisition of Peloton Therapeutics, providing access to the experimental glioblastoma drug PT2977. This strategic move is anticipated to fortify Merck's pipeline and enhance its future revenue-generating capabilities.
These developments underscore the proactive efforts of key providers in the glioblastoma multiforme treatment sector to advance innovative therapies and broaden their market presence.
Market Segments Covered in Glioblastoma Multiforme Treatment Market Analysis
By Treatment :
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Tumor Treating Field (TTF) Therapy
Immunotherapy
By Drug Class :
Temozolomide
Bevacizumab
Carmustine Wafers
Other Drug Classes
Lomustine
By Application :
Hospitals
Clinics
Ambulatory Surgical Centers
By Region :
North America
Latin America
Europe
APAC
MEA
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=7187
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Treatment Market to Surge 10.1% Growth Expected 2022-2032 here
News-ID: 3290626 • Views: …
More Releases from Fact MR
Gene Delivery Systems Market is expected to reach US$ 4.1 billion by 2027.
The current valuation of the worldwide Gene Delivery Systems Market (遺伝子デリバリーシステム市場) stands at US$ 3 billion, with projections indicating it will rise to US$ 4.1 billion by the conclusion of 2027. Anticipated growth suggests a steady increase in global demand for gene delivery systems, with a forecasted Compound Annual Growth Rate (CAGR) of 6.5% from 2022 to 2027.
The gene delivery systems market encompasses a wide range of technologies and approaches…
Gas Spring Market is projected to climb to US$ 7.04 billion by 2033.
By 2033, it is expected that the Global Gas Spring Market (ガススプリング市場), which peaked at US$ 3.88 billion in 2023, will have grown to US$ 7.04 billion. The gas spring market is expected to grow at a compound annual growth rate (CAGR) of 6.1% from 2023 to 2033.
Insights into the Gas Spring market reveal a steady increase in demand, driven by factors such as growing industrialization, urbanization, and the…
Off-Highway Engine Market Size is expected to reach US$ 158.2 billion by 2032
In 2022, the worldwide Off-Highway Engine Market (オフハイウェイエンジン市場) has achieved a value of US$ 88,031.9 million. It is anticipated to advance at a Compound Annual Growth Rate (CAGR) of 6.03%, reaching US$ 158.2 billion by 2032.
The Off-Highway Engine market encompasses a diverse range of engines utilized in various off-road applications, including construction, agriculture, mining, and industrial sectors. These engines power a wide array of equipment such as excavators, tractors, bulldozers,…
Unsaturated Polyester Resin Market is thus estimated to secure a revenue of US$ …
The present value of the worldwide Unsaturated Polyester Resin Market (不飽和ポリエステル樹脂市場) stands at US$ 13.1 billion, with projections indicating a growth rate of 5.5% CAGR from 2023 to 2033. Consequently, it is anticipated that by the conclusion of this forecast period, the global demand for unsaturated polyester resins will yield revenue reaching US$ 22.5 billion.
The Unsaturated Polyester Resin (UPR) market has witnessed significant growth and evolution in recent years, driven…
More Releases for Glioblastoma
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
Glioblastoma Treatment Drugs Market : Drivers, Restraint & Future Growth
Brain tumors is one of the leading cause of cancer which is common among children and teenagers. Glioblastoma (GBM) is most common grade four tumor, is malignant and contains dead tumor cells. It is also called as Glioblastoma multiforme, it has variants of giant cell Glioblastoma and gliosarcoma found in cerebral hemisphere of brain. The exact cause of this tumor is not known but is also found in spinal cord…
Glioblastoma Multiforme Treatment Market : Global Glioblastoma Multiforme Treatm …
Glioblastoma Multiforme Treatment Market
Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
Glioblastoma multiforme is the high-grade glioma and…
Glioblastoma Multiforme Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial…
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging…
